NRAS
HGNC:7989 · 40 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | NRAS | “Recurrent primary hyperparathyroidism with ipsilateral multifocal papillary thyroid carcinoma of classical, warthin-like, and follicular variants harboring distinct BRAF and NRAS mutations: a rare case report.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “RESULTS: Seven patients with mutations in C1q, DNase1L3, PRKCD, and NRAS were included.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Histopathologic examination confirmed CD68+/CD163+ histiocytes harboring BRAF V600E/D and NRAS mutations.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Circulating tumor DNA (ctDNA) enables the quantitative tracking of BRAF, NRAS, and TERT mutations using droplet digital PCR (ddPCR) and next-generation sequencing (NGS).” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Highly focused treatments have been developed as a result of significant genetic mutations, such as those in BRAF, NRAS, and KIT, as well as changes in signaling pathways, such as MAPK and PI3K/AKT/mTOR.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “The RAS family of oncoproteins (KRAS, HRAS, and NRAS) drive aggressive cancers like pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), yet targeting mutant RAS has historically been challenging due to its "undruggable" structure.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “NRAS, HRAS and TP53 mutations showed no significant difference.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “We performed next-generation sequencing and found mutations in the TP53, NRAS, EGFR PDGFR, MET, KIT, ERBB2, and GUSP genes.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “The three isoforms of the RAS gene are HRAS, NRAS, and KRAS.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Combinational Inhibition of MEK and AKT Synergistically Induces Melanoma Stem Cell Apoptosis and Blocks NRAS Tumor Growth.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “The mutational spectrum of NRAS gene discovers a novel frameshift mutation (E49R) in Saudi colorectal cancer patients.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “This disorder stems from melanoblast abnormalities and NRAS gene mutations.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “In colorectal cancer, KRAS (39.0%), NRAS (8.0%), and BRAF (V600E, 4.0%) were the most observed mutations among genes recommended by the NCCN.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Targeted next-generation sequencing (NGS) was used to detect BRAF, NRAS, KRAS, HRAS, RET/PTC fusions, and TERT promoter mutations.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “The molecular analysis results unveiled mutations in specific genes (FLT3, KIT, PTPN11, BCR, DNMT3A, and NRAS) targeted by nine microRNAs.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “NRAS mutations predominated at 67 % compared to HRAS (24 %) and KRAS (12 %).” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “In silico Screening and Validation of Achyranthes aspera as a Potential Inhibitor of BRAF and NRAS in Controlling Thyroid Cancer.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “RESULTS: Three tumors were tested only by Sanger sequencing and were negative for BRAFV600E, HRAS, KRAS, NRAS, TERT promoter, PTEN, and PIK3CA mutations.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “METHODS: In total, 694 patients from the clinical trials COIN and COIN-B had MAPK-activated CRCs (assigned as KRAS, NRAS, or BRAF mutant).” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Human malignancies typically show mutations in the Ras gene including HRAS, KRAS, and NRAS.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Seven patients had single-gene TERT promoter mutations, and 17 had concurrent mutations, including BRAF V600E, HRAS, NRAS, PIK3CA, and EIF1AX.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “METHODS: An extensive electronic systematic review following the PRISMA guidelines was performed for English-language papers using the following databases as sources of information: PubMed, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Library Genesis, Worldwide Science, National Rheumatoid Arthritis Society (NRAS), and other related articles.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Computational Analysis of Deleterious SNPs in NRAS to Assess Their Potential Correlation With Carcinogenesis.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “The activated mutations in Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) and Kirsten rat sarcoma viral oncogene homolog (KRAS) confers proliferative and survival signals, deliberating numerous effects on overall survival and progression free survival in AML patients.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “OBJECTIVES: KRAS, NRAS, and BRAF mutations are commonly present in colorectal cancer (CRC).” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Mutations in known driver genes including BRAF, NRAS, and HRAS were shared and preferentially clonal in both sites.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Other genetic alterations including EML4-NTRK1, EML4-ALK, NRAS, KRAS, PTEN, and CREBBP occurred once each.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Screening of RAS (Kirsten rat sarcoma viral oncogene homolog (KRAS), neuro-blastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF)) somatic mutations is necessary prior to considering anti-epidermal growth factor receptor (EGFR) therapies in CRC patients.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “We evaluated variants in the following genes: BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NF1, NRAS, PTPN11, RAF1, SHOC2, and SOS1.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “This study comprehensively investigated a large series of pediatric DTC for single point mutations in BRAF, HRAS, KRAS, NRAS, PIK3CA, PTEN, and TERT.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “By generating an inducible transgenic mouse model we showed an oncogenic role for a truncating PREX2 mutation (PREX2(E824)*) in vivo in the context of mutant NRAS.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Frequently mutated genes were: TP53 (39.6%), KRAS exons 3/4 (8.8%), NRAS exons 2/3 (7.1%), PIK3CA exons 9/20 (13.2%), BRAF (8.2%).” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Mutation in BRAF exon 15, KRAS, NRAS, and HRAS were studied by polymerase chain reaction (PCR)-sequencing of tumor DNA; RET/PTC rearrangement was determined by reverse transcription (RT)-PCR-sequencing of tumor cDNA.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Spontaneous remission of juvenile myelomonocytic leukemia with NRAS mutation.” | 0.98 | hgnc_dict_v1 |
| gene | NRAS | “Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.” | 0.98 | hgnc_dict_v1 |